Clinical Trials Sponsored by MacuHealth LP

Total 288 results

MaiHealth Inc

Unknown

Longitudinal Study of Multi-Analyte Profile for Dyslipidemia

Dyslipidemia

United States
Felipe Medeiros, MD
Heidelberg Engineering GmbH; MacuHealth LP; Industrial Orgánica S.A. de C.V.

Terminated

Macular Pigment and Visual Performance in Glaucoma Patients

Glaucoma

United States
Janssen, LP

Completed

A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

Schizophrenia | Psychotic Disorder
Janssen, LP

Completed

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) (SOURCE)

Schizophrenia

United States
Janssen, LP

Completed

A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

Schizophrenia
Janssen, LP

Completed

Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen, LP

Completed

A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.

Schizophrenia | Schizoaffective Disorder
PHCC LP

Completed

Reducing Preterm Births in Underserved Pregnant Women

Preterm Birth | Low Birth Weight <2500 Grams | Verylow Birthweight <1500 Grams

United States
Janssen, LP

Completed

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Diabetes Mellitus | Schizophrenia
Janssen, LP

Completed

A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia

Dementia | Alzheimer Disease | Dementia, Vascular
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Penn State University
Orlando Regional Medical Center; MacuHealth

Not yet recruiting

Carotenoids for Collision Athletes

Head Injury | Carotenoids

United States
Ellodi Pharmaceuticals, LP

Active, not recruiting

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) (FLUTE-3)

Eosinophilic Esophagitis

United States, Canada
Purdue Pharma LP

Terminated

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

Attention Deficit/Hyperactivity Disorder

United States
Purdue Pharma LP

Withdrawn

Clinical Outcomes From Nalmefene (COINED)

Opioid Overdose
Ellodi Pharmaceuticals, LP

Completed

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) (FLUTE-2)

Eosinophilic Esophagitis

United States, Australia, Spain
Bayer
Janssen, LP

Completed

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid (XATOA)

Atherosclerosis

Germany, Argentina, Brazil, Canada, Denmark, Israel, Korea, Republic of, Lebanon, Luxembourg, Mexico, Norway, Russian Federation, Slovenia, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom
Bayer
Janssen, LP

Completed

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (SiERRA UK)

Atrial Fibrillation

United Kingdom
Purdue Pharma LP

Completed

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Pain

United States, Israel, Spain, United Kingdom, Greece, Hungary, New Zealand, Romania
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

ECG Effects

United States
Purdue Pharma LP

Completed

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

Pain

United States
Purdue Pharma LP

Completed

Experimental Biomarker Study for Pain Thresholds

Pain

Denmark
Purdue Pharma LP

Completed

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain (Palladone)

Postoperative Pain

United States
Purdue Pharma LP

Completed

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Bayer
Janssen, LP

Completed

Real-Life Evidence on Stroke Prevention in SPAF (RELIEF)

Atrial Fibrillation (Prevention of Stroke)

Germany
Purdue Pharma LP

Completed

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Healthy

United States
Purdue Pharma LP

Terminated

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Postsurgical Pain Due to Third Molar Extraction

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis, Knee

United States
Purdue Pharma LP

Completed

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Chronic Nonmalignant Pain

United States
Purdue Pharma LP

Terminated

Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

Postoperative Pain

United States
Purdue Pharma LP

Completed

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Osteoarthritis

United States
Purdue Pharma LP

Completed

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Healthy

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain. (BP96-0604)

Back Pain

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States
Purdue Pharma LP

Completed

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Ellodi Pharmaceuticals, LP

Available

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Ellodi Pharmaceuticals, LP

Completed

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial (FLUTEEN)

Eosinophilic Esophagitis

Australia, United States
Purdue Pharma LP

Terminated

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

Osteoarthritis Pain of the Knee

United States
Purdue Pharma LP

Withdrawn

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Other Acute Postoperative Pain | Prolonged Endotracheal Intubation
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

Back Pain

United States
Purdue Pharma LP

Completed

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

Chronic Pain | Osteoarthritis of the Knee

United States
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Osteoarthritis

United States
Purdue Pharma LP

Completed

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Healthy Volunteers

United States
Purdue Pharma LP

Terminated

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

Osteoarthritis

United States

3

Subscribe